William Blair analyst Brandon Vazquez has maintained their bullish stance on PRCT stock, giving a Buy rating on February 26.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight the potential for significant growth and opportunity in PROCEPT BioRobotics. The company’s stock has experienced a substantial decline, creating an attractive entry point for investors, especially with the valuation now halved from its previous highs. Vazquez points to the promising growth trajectory projected for 2025, with expectations of 40% sales growth and enhanced profitability, as a key reason for his optimistic outlook.
Additionally, several upcoming clinical data catalysts are anticipated to drive further interest and confidence in the company’s prospects. The March 2025 Water III study and the April 2025 PRCT001/002 studies are expected to provide valuable insights into the company’s core areas of benign prostatic hyperplasia (BPH) and prostate cancer. These studies, along with the planned Water IV RCT, are seen as pivotal in potentially expanding the company’s market presence and enhancing its growth story. Vazquez emphasizes that during periods of market volatility, such opportunities present a favorable risk/reward profile for investors seeking to capitalize on strong growth narratives.
Vazquez covers the Healthcare sector, focusing on stocks such as PROCEPT BioRobotics, DENTSPLY SIRONA, and Henry Schein. According to TipRanks, Vazquez has an average return of 1.8% and a 27.27% success rate on recommended stocks.
In another report released on February 26, TD Cowen also reiterated a Buy rating on the stock with a $85.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com